Five Prime Therapeutics Inc (FPRX) 2016年年度报告「NASDAQ」.pdf

1、FIVE PRIME THERAPEUTICS INCFORM 10-K(Annual Report)Filed 02/24/17 for the Period Ending 12/31/16 AddressTWO CORPORATE DRIVESOUTH SAN FRANCISCO,CA 94080Telephone415-365-5600CIK0001175505SymbolFPRXSIC Code2834-Pharmaceutical PreparationsIndustryBiotechnology&Medical ResearchSectorHealthcareFiscal Year

2、12/31http:/www.edgar- Copyright 2017,EDGAR Online,Inc.All Rights Reserved.Distribution and use of this document restricted under EDGAR Online,Inc.Terms of Use.UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXC

3、HANGE ACT OF 1934For the fiscal year ended December 31,2016orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to Commission File Number:001-36070Five Prime Therapeutics,Inc.(Exact name of registrant as specified in its charter)Dela

4、ware26-0038620(State or other jurisdiction ofincorporation or organization)(IRS EmployerIdentification No.)Two Corporate DriveSouth San Francisco,California 94080(415)365-5600(Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Securities re

5、gistered pursuant to Section 12(b)of the Act:Title of Each ClassName of Each Exchange on Which RegisteredCommon Stock,par value$0.001 per shareNasdaq Global Select MarketSecurities registered pursuant to Section 12(g)of the Act:NoneIndicatebycheckmarkiftheregistrantisawell-knownseasonedissuer,asdefi

6、nedinRule405oftheSecuritiesAct.YesNoIndicatebycheckmarkiftheregistrantisnotrequiredtofilereportspursuanttoSection13or15(d)oftheAct.YesNoIndicatebycheckmarkwhethertheregistrant(1)hasfiledallreportsrequiredtobefiledbySection13or15(d)oftheSecuritiesExchangeActof1934duringthepreceding12months(orforsuchs